The TRANSLATE-TIMI 70 trial, a dose-ranging phase 2b study with the ANGPTL3 antisense vupanorsen in subjects with dyslipidemia, met its primary endpoint: a significant reduction of non-HDL-c at 24 weeks with vupanorsen compared to placebo.
What are triglyceride-rich lipoprotein (TGRL) remnants? How do TGRL remnants differ from LDL and do these differences make them more atherogenic? Prof. Henry Ginsberg answers these questions in this video.
What is the role of icosapent ethyl in lowering residual CV risk? Prof. Steg answers this question by presenting observations from trials with EPA-based therapies.
Many questions remain on the subject of triglycerides, EPA-based therapies and CV outcomes. Three discussants attempt to unravel the mysteries in this field.
It is relevant to discuss hypertriglyceridemia when LDL-c and inflammation are well-controlled? Prof. Stroes discusses the association of triglycerides and triglycerde-rich lipoproteins with CV risk.
Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.
What is the relationship between triglyceride-rich lipoproteins and CV risk? And what is the role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins? Peter Libby answers these and other questions in this video.
ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.
The ACC has published an Expert Consensus Decision Pathway which provides practical recommendations on lifestyle modifications in patients with hypertriglyceridemia and use of statins and TG risk-based non-statin therapies for ASCVD risk reduction.
This meta-analysis of five RCTs (REDUCE-IT, ASCEND, R&P, STRENGTH and OMEMI) showed that omega-3 fatty acids supplementation is associated with an increased risk of incident AF, compared to placebo.
ACC 2021 This subanalysis of the EVAPORATE trial showed a significant reduction in whole-heart atherosclerotic plaque burden over 18 months in statin-treated patients with elevated triglyceride levels who received icosapent ethyl compared to those on placebo.
ACC 2021 A phase 2 study showed that evinacumab resulted in reduction of TGs in patients with severe hypertriglyceridemia, but lowering was variable and dependent on genotype.